Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Document › Details

Promethera Biosciences S.A.. (10/5/18). "Press Release: Promethera Biosciences Appoints Mutsuki Takano to Group Chief Financial Officer". Mont-Saint-Guibert.

Region Region Tokyo
  Country Japan
Organisations Organisation Promethera Biosciences S.A.
  Group Promethera (Group)
  Organisation 2 Promethera Biosciences, Tokyo
  Group Promethera (Group)
Products Product HepaStem cell therapy product
  Product 2 cell therapy
Persons Person Takano, Mutsuki (Promethera 201810– Group CFO joined 7/18 as General Manager Promethera Japan before Mitsui)
  Person 2 Hazevoets, Frank (Promethera Biosciences 201601 CFO + Head of Corporate Development LEFT 10/18)

Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced that Mutsuki Takano, currently Branch General Manager of Promethera Biosciences Japan Branch and Member of the Management Team of Promethera Biosciences SA will succeed Frank Hazevoets as Group Chief Financial Officer (Group CFO), in addition to his current responsibilities.

“We look forward to working with Mutsuki in his expanded role as Group Chief Financial Officer and General Manager of our branch office in Japan. The management change reflects the greater importance of the Asian markets for Promethera”, commented John Tchelingerian, PhD, President and CEO at Promethera. “On behalf of both the Board and the Executive Management, I would like to express my heartfelt thanks to Frank Hazevoets for his commitment to helping build Promethera over the past four years. We wish him all the best for the future.”

“I am honored to serve Promethera Biosciences as part of the global leadership team in addition to leading the expansion of our business development and corporate development activities in Asia,” commented Mutsuki Takano, Group Chief Financial Officer and Branch General Manager of Promethera Biosciences Japan Branch.

About Promethera Biosciences

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to enable patients to overcome acute and chronic liver diseases. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immunemodulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the anti-TNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera®, HepaStem®, H2stem®, Cytonet®, Heparesc® are all registered trademarks of the PROMETHERA group.

Contact Information:

Promethera Biosciences SA
Alexandra Schiettekatte

For media: MacDougall Communications
Mario Brkulj or Shai Biran, Ph.D.
+49 89 2420 9345 or +1 781-235-3060

Record changed: 2019-08-19


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Promethera (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top